デフォルト表紙
市場調査レポート
商品コード
1470832

体外診断薬市場:構成要素、技術、検体、用途、エンドユーザー別-世界予測2024-2030年

In-Vitro Diagnostics Market by Component (Data Management Software & Services, Instruments, Reagents & Kits), Technology (Clinical Chemistry, Coagulation & Hemostasis, Hematology), Specimen, Application, End User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
体外診断薬市場:構成要素、技術、検体、用途、エンドユーザー別-世界予測2024-2030年
出版日: 2024年04月17日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

体外診断薬市場規模は、2023年に1,090億5,000万米ドルと推定され、2024年には1,150億4,000万米ドルに達し、CAGR 6.11%で2030年には1,652億7,000万米ドルに達すると予測されています。

体外診断薬(IVD)は、人体外の生物学的サンプルを実験室で分析するヘルスケア産業の重要な側面です。これらの診断検査は、個人の健康状態に関する貴重な情報を提供することで、疾病予防、早期発見、標的治療において重要な役割を果たしています。体外診断用医薬品には、正確な診断と患者に合わせた治療計画を促進するための様々な医療機器、アッセイ、試薬、分析機器が含まれます。IVD検査は、血液、尿、唾液、組織生検、その他の体液などの複数の生物学的検体に対して実施されます。検査結果は、ヘルスケア専門家が診断、予後、治療法の選択、疾病管理に関して十分な情報に基づいた決定を下す際に役立ちます。世界の高齢化人口の増加と慢性疾患の蔓延は、市場成長の重要な要因です。疾病の早期発見に対する意識の高まりと、先進的で自動化された機器の採用は、市場の採用を増加させると予想されます。世界の様々な保健当局や機関が課す厳しい規制やガイドライン、複雑な償還制度が市場成長の妨げになる可能性があります。体外診断用医薬品(IVD)業界の技術革新は、高い精度を維持しながら所要時間を短縮するポータブル機器による迅速な検査結果を可能にすることで、業界情勢を一変させつつあります。

主な市場の統計
基準年[2023] 1,090億5,000万米ドル
予測年[2024] 1,150億4,000万米ドル
予測年 [2030] 1,652億7,000万米ドル
CAGR(%) 6.11%

コンポーネント体外診断薬に不可欠な機器、試薬の役割

体外診断薬のデータ管理ソフトウェアは、診断検査によって生成される膨大な量のデータを扱い、分析するために設計されています。患者情報、検査結果、検査室のワークフローを効率的に管理します。診断機器は、採取した生体サンプルの検査や分析を行うために使用されます。これらの機器には、ピペットや遠心分離機などの単純な手動機器から、最小限の人的介入で複数の検査を同時に実行する複雑な自動化システムまで含まれます。試薬とキットは、診断検査を実施するために体外診断薬機器と共に使用される重要な消耗品です。試薬は特定のサンプル成分と反応し、測定可能なシグナルを生成したり、目的の分析物を検出する化学物質です。ソフトウェアや消耗品に加え、診断機器のメンテナンスやサポート、検査室担当者のトレーニングプログラム、規制遵守に関するコンサルティング、品質管理システム、検査法のバリデーション支援などのサービスも提供しています。

アプリケーションがん医療における体外診断薬アプリケーションの革新

体外診断薬(IVD)は、自己免疫疾患の診断に重要な役割を果たし、効果的な治療戦略を可能にします。酵素結合免疫吸着測定法(ELISA)や免疫蛍光検査などの体外診断薬技術は、これらの疾患に特異的な自己抗体の同定にますます使用されるようになっています。心臓病学 IVD検査は、心臓発作、心不全、高血圧を含む心血管疾患(CVD)の診断とリスク評価に役立ち、トロポニン、クレアチンキナーゼ-MB(CK-MB)、B型ナトリウム利尿ペプチド(BNP)などの心臓バイオマーカーを測定して心臓障害を特定し、心臓の健康状態を監視します。IVDは、正確で迅速なグルコース検査ソリューションを提供することにより、糖尿病管理において重要な役割を果たしています。血糖測定器、持続グルコースモニタリング(CGM)装置、HbA1c検査は糖尿病治療に不可欠なIVDツールです。腎臓学では、IVD検査は腎臓病、電解質不均衡、腎機能の検出とモニタリングに使用され、これには血清クレアチニン、血中尿素窒素(BUN)、尿タンパク測定などの一般的な検査が含まれます。リキッドバイオプシーや次世代シーケンシング(NGS)を含むIVD技術の進歩は、早期発見、個別化治療、治療反応のモニタリングをサポートする低侵襲検査の選択肢を提供することで、がん診断に変革をもたらしつつあります。

地域別の洞察

南北アメリカは、信頼性の高い性能と競争力のある価格設定によって際立った強力な製品ラインを持つ機器やアクセサリーを開発する主要メーカーの存在により、体外診断市場において重要な地位を占めています。同地域の高度なヘルスケアインフラ、高い医療費、有利な償還政策が体外診断用医薬品技術の普及に寄与しています。欧州では、機器、ソフトウェア、品質管理用消耗品など複数のプラットフォームやフォーマットを含む、より包括的なソリューションを提供するための研究開発活動が行われています。EMEA(欧州・中東・アフリカ)地域のプロバイダーが採用している戦略には、地理的プレゼンスを拡大するために、現地の販売代理店との提携や小規模なIVD企業の買収が含まれます。アジア太平洋地域では、人口の増加、ヘルスケア支出の増加、慢性疾患や感染症の流行などの要因により、体外診断用医薬品市場が急速に成長しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは体外診断薬市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、体外診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1.体外診断薬市場の市場規模および予測は?

2.体外診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3.体外診断薬市場の技術動向と規制枠組みは?

4.体外診断薬市場における主要ベンダーの市場シェアは?

5.体外診断薬市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 慢性疾患および感染症の蔓延の増加
      • 個別化治療への注目の高まりとコンパニオン診断の導入増加
      • 健康啓発キャンペーンと検査に対する政府の好ましい取り組み
    • 抑制要因
      • 特定の診断検査に対する包括的な償還ポリシーの欠如
    • 機会
      • ヘルスケアインフラの拡大とポイントオブケア検査の拡大
      • 診断とデジタルヘルスプラットフォームの統合
    • 課題
      • 体外診断に関連する厳格な規制と承認プロセス
  • 市場セグメンテーション分析
    • コンポーネント:体外診断薬における機器と試薬の不可欠な役割
    • アプリケーション:がん治療における体外診断の革新的な応用
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 体外診断薬市場:コンポーネント別

  • データ管理ソフトウェアとサービス
  • 機器
  • 試薬とキット

第7章 体外診断薬市場:技術別

  • 臨床化学
  • 凝固と止血
  • 血液学
  • 免疫化学
  • 微生物学
  • 分子診断
  • 尿検査

第8章 体外診断薬市場標本別

  • 血液、血清、血漿
  • 唾液
  • 尿

第9章 体外診断薬市場:用途別

  • 自己免疫疾患
  • 心臓病学
  • 糖尿病
  • 薬物検査
  • HIV/エイズ
  • 感染症
  • 腎臓学
  • 腫瘍学

第10章 体外診断薬市場:エンドユーザー別

  • 病院と介護サービス提供者
  • 研究所
  • 患者の自己検査

第11章 南北アメリカの体外診断薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域の体外診断薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカの体外診断薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス、2023
  • 競合シナリオ分析
    • バイオケアメディカルの高度な抗原回復チャンバー(ARC)は免疫組織化学に革命をもたらします
    • GenWorks Health、デング熱とマラリアのIVD検査を開始
    • オックスフォード・ナノポアとビオメリューが革新的な感染症診断法の開発に向けて戦略的提携契約を締結
  • 戦略分析と提言

第15章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. IN-VITRO DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. IN-VITRO DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BASIC METABOLIC PANEL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BASIC METABOLIC PANEL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIPID PROFILE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIPID PROFILE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RENAL PROFILE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RENAL PROFILE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIALTY CHEMICAL TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIALTY CHEMICAL TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSPOT ASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSPOT ASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 76. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 77. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 78. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 79. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 80. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 81. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 82. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 83. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 84. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 85. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 86. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 87. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 90. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 91. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 92. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 93. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 94. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 95. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DRUG TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 96. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DRUG TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 97. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 98. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 99. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 100. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 101. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEPHROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 102. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEPHROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 103. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 104. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 105. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 106. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 107. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 108. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 109. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 110. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 111. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT SELF-TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 112. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT SELF-TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 113. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 114. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 115. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 116. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 117. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 118. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 119. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 120. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 121. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 122. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 123. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 124. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 125. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 126. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 127. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 130. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 131. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 132. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 133. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 134. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 135. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 136. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 137. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 138. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 139. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 140. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 141. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 142. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 143. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 144. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 145. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 146. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 147. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 150. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 151. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 152. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 153. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 154. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 155. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 156. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 157. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 158. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 159. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 160. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 161. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 162. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 163. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 164. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 165. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 168. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 169. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 170. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 171. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 174. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 175. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 176. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 177. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 178. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 179. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 180. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 181. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 182. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 183. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 188. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 189. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 190. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 191. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 192. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 193. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 194. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 195. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 196. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 197. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 198. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 199. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 200. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 201. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 204. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 205. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 206. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 207. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 208. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 209. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 210. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 211. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 212. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 213. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 214. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 215. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 216. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 217. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 218. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 219. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 222. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 223. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 224. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 245. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 246. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 247. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 248. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 249. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 250. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 251. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 252. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 253. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 254. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 255. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 256. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 257. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 258. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 259. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 262. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 263. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 264. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 265. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 266. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 267. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 268. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 269. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 270. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 271. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 272. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 273. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 274. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 275. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 276. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 277. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 280. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 281. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 282. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 283. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 284. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 285. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 286. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 287. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 288. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 289. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 290. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 291. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 292. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 293. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 294. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 295. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 298. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 299. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 300. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 301. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 302. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 303. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 304. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 305. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 306. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 307. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 308. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 309. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 310. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2024-2030 (USD MILLION)
  • TABLE 311. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 312. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 313. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 314. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 315. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 316. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 317. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2023 (USD MILLION)
  • TABLE 318. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024-2030 (USD MILLION)
  • TABLE 319. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 320. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 321. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 322. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 323. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2023 (USD MILLION)
  • TABLE 324. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2024-2030 (USD MILLION)
  • TABLE 325. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2023 (USD MILLION)
  • TABLE 326. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2024-2030 (USD MILLION)
  • TABLE 327. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2023 (USD MILLION)
  • TABLE 328. JAPAN IN-
目次
Product Code: MRR-434CCDA04D33

[190 Pages Report] The In-Vitro Diagnostics Market size was estimated at USD 109.05 billion in 2023 and expected to reach USD 115.04 billion in 2024, at a CAGR 6.11% to reach USD 165.27 billion by 2030.

In-vitro diagnostics (IVD) is a critical aspect of the healthcare industry that involves the analysis of biological samples outside of the human body in a laboratory setting. These diagnostic tests play a crucial role in disease prevention, early detection, and targeted therapies by providing valuable information on an individual's health status. IVD encompasses various medical devices, assays, reagents, and analytical instruments to facilitate accurate diagnoses and personalized patient treatment plans. IVD testing is performed on multiple biological specimens, such as blood, urine, saliva, tissue biopsies, or other bodily fluids. The test results aid healthcare professionals in making informed decisions regarding diagnosis, prognosis, therapy selection, and disease management. The increasing global aging population and prevalence of chronic diseases are significant factors contributing to market growth. Rising awareness of early disease detection and the adoption of advanced and automated instruments is expected to increase market adoption. Stringent regulations and guidelines imposed by various health authorities and agencies worldwide and complex reimbursement systems may hamper the market growth. Technological innovations within the IVD industry are transforming the landscape by enabling rapid test results with portable devices that reduce turnaround time while maintaining high levels of accuracy.

KEY MARKET STATISTICS
Base Year [2023] USD 109.05 billion
Estimated Year [2024] USD 115.04 billion
Forecast Year [2030] USD 165.27 billion
CAGR (%) 6.11%

Component: The integral role of instruments, and reagents in in-vitro diagnostics

Data management software in in-vitro diagnostics is designed to handle and analyze the vast amount of data generated by diagnostic tests. This software helps manage patient information, test results, and laboratory workflow efficiently. Diagnostic instruments are used to conduct tests and analyses on collected biological samples. These instruments include simple manual devices, such as pipettes and centrifuge and complex automated systems that simultaneously perform multiple tests with minimal human intervention. Reagents & kits are crucial consumables used in conjunction with in-vitro diagnostics instruments to perform diagnostic tests. Reagents are chemical substances that react with specific sample components to produce measurable signals or detect analytes of interest. In addition to software and consumables, services include maintenance and support for diagnostic equipment, training programs for laboratory personnel, consulting on regulatory compliance, quality management systems, and assistance with test method validation.

Application: Revolutionizing application of in-vitro diagnostic in cancer care

In-vitro diagnostics (IVD) plays a critical role in diagnosing autoimmune diseases to enable effective treatment strategies. In-vitro diagnostics technologies such as enzyme-linked immunosorbent assays (ELISA) and immunofluorescence tests are increasingly used for identifying autoantibodies specific to these conditions. Cardiology IVD tests aid in the diagnosis and risk assessment of cardiovascular diseases (CVD), including heart attacks, heart failure, and hypertension, that help in measuring cardiac biomarkers, including troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP) to identify cardiac injury and monitor heart health. IVD plays a vital role in diabetes management by providing accurate and rapid glucose testing solutions. Blood glucose meters, continuous glucose monitoring (CGM) devices, and HbA1c tests are essential IVD tools in diabetes care. In nephrology, IVD tests are employed for detecting and monitoring kidney diseases, electrolyte imbalances, and kidney function, which includes Common tests such as serum creatinine, blood urea nitrogen (BUN), and urine protein measurements. Advancements in IVD technologies, including liquid biopsies and next-generation sequencing (NGS), are transforming cancer diagnostics by offering minimally invasive testing options that support early detection, personalized therapies, and monitoring treatment response.

Regional Insights

The Americas has a significant landscape in the in-vitro diagnostic market owing to the presence of key manufacturers that develop instruments and accessories with strong product lines distinguished by reliable performance and competitive pricing. The region's advanced healthcare infrastructure, high healthcare spending, and favorable reimbursement policies contribute to the widespread adoption of IVD technologies. In Europe, market players are conducting R&D activities to offer more comprehensive solutions, including multiple platforms and formats such as instrumentation, software, and consumables for quality control. Strategies adopted by providers in the EMEA region include partnerships with local distributors and acquisitions of smaller IVD companies to expand their geographical presence. The Asia-Pacific region observed a rapidly growing market for IVD, driven by factors, such as a growing population base, increasing healthcare expenditure, and a rising prevalence of chronic and infectious diseases.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the In-Vitro Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the In-Vitro Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Abbott Laboratories, Adaptive Biotechnologies Corp, Agilent Technologies Inc., Arkray Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biomerieux SA, Danaher Corporation, DiaSorin S.p.A., EKF GmbH, F. Hoffmann-La Roche Ltd., Grifols SA, Hologic, Inc., Illumina, Inc., Menarini Diagnostics, Mindray Medical International Limited, Myriad Genetics, Inc., Ortho-Clinical Diagnostics, Inc., Qiagen GmbH, Randox Laboratories, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Component
    • Data Management Software & Services
    • Instruments
    • Reagents & Kits
  • Technology
    • Clinical Chemistry
      • Basic Metabolic Panel
      • Electrolyte Panel
      • Lipid Profile
      • Liver Panel
      • Renal Profile
      • Specialty Chemical Tests
      • Thyroid Function Panel
    • Coagulation & Hemostasis
    • Hematology
    • Immunochemistry
      • Enzyme-Linked Immunosorbent Assay
        • Chemiluminescence Immunoassays
        • Colorimetric Immunoassays
        • Fluorescence Immunoassays
      • Enzyme-Linked Immunospot Assays
      • Radioimmunoassay
      • Rapid Test
      • Western Blotting
    • Microbiology
    • Molecular Diagnostics
      • DNA Sequencing & Next-Generation Sequencing
      • Hybridization
      • Isothermal Nucleic Acid Amplification Technology
      • Microarray
      • Polymerase Chain Reaction
    • Urinalysis
  • Specimen
    • Blood, Serum & Plasma
    • Saliva
    • Urine
  • Application
    • Autoimmune Diseases
    • Cardiology
    • Diabetes
    • Drug Testing
    • HIV/Aids
    • Infectious Diseases
    • Nephrology
    • Oncology
  • End User
    • Hospitals & Care Providers
    • Laboratories
    • Patient Self-Testing
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the In-Vitro Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the In-Vitro Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the In-Vitro Diagnostics Market?

4. What is the market share of the leading vendors in the In-Vitro Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the In-Vitro Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic and infectious diseases
      • 5.1.1.2. Growing focus on personalized treatment coupled with increased adoption of companion diagnostics
      • 5.1.1.3. Favourable government initiative for health awareness campaigns and screenings
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of comprehensive reimbursement policies for certain diagnostic tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of point-of-care testing coupled with growing healthcare infrastructure
      • 5.1.3.2. Integration of diagnostics with digital health platforms
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and approval processes associated with in vitro diagnostics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: The integral role of instruments, and reagents in in-vitro diagnostics
    • 5.2.2. Application: Revolutionizing application of in-vitro diagnostic in cancer care
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. In-Vitro Diagnostics Market, by Component

  • 6.1. Introduction
  • 6.2. Data Management Software & Services
  • 6.3. Instruments
  • 6.4. Reagents & Kits

7. In-Vitro Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Clinical Chemistry
  • 7.3. Coagulation & Hemostasis
  • 7.4. Hematology
  • 7.5. Immunochemistry
  • 7.6. Microbiology
  • 7.7. Molecular Diagnostics
  • 7.8. Urinalysis

8. In-Vitro Diagnostics Market, by Specimen

  • 8.1. Introduction
  • 8.2. Blood, Serum & Plasma
  • 8.3. Saliva
  • 8.4. Urine

9. In-Vitro Diagnostics Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Cardiology
  • 9.4. Diabetes
  • 9.5. Drug Testing
  • 9.6. HIV/Aids
  • 9.7. Infectious Diseases
  • 9.8. Nephrology
  • 9.9. Oncology

10. In-Vitro Diagnostics Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals & Care Providers
  • 10.3. Laboratories
  • 10.4. Patient Self-Testing

11. Americas In-Vitro Diagnostics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific In-Vitro Diagnostics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa In-Vitro Diagnostics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Biocare Medical's Advanced Antigen Retrieval Chamber (ARC), Revolutionizing Immunohistochemistry
    • 14.3.2. GenWorks Health launches IVD tests for dengue & malaria
    • 14.3.3. Oxford Nanopore and bioMerieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio